18F-FDG PET/CT在原发灶不明的脑转移瘤中的诊断价值

目的 探讨18F-FDG PET/CT在查找原发灶不明的脑转移瘤中的价值。 方法 回顾性分析17例原发灶不明的脑转移瘤患者的全身18F-FDG PET/CT检查资料。 结果 17例患者均经活检确诊原发灶,准确率100%。原发性肺癌13例,占76%,其中有2例在第二次行PET/CT检查时才检出原发灶;原发性肝癌2例,占12%;原发性贲门癌1例,占6%;原发性升结肠癌1例,占6%。在检查到原发灶的基础上,18F-FDG PET/CT亦发现10例合并转移者,其中合并肺转移者2例、合并淋巴结转移者3例、合并骨转移者2例及合并其他部位转移者3例,共发现病灶61处;2例肝癌患者单发脑转移灶中均有脑卒中。 结论 18F-FDG PET/CT在查找原发灶不明的脑转移瘤原发灶中有重要价值,并为临床分期及治疗提供有利帮助。     

全身18F FDG PET CT在脑转移瘤诊断中的应用

目的评价全身18F 氟脱氧葡萄糖（18F fluorodeoxyglucose,18F FDG）正电子发射断层扫描(positron emission tomography,PET) CT显像在脑转移瘤的诊断及寻找原发灶中的应用价值。方法对全身脑转移瘤及可疑脑转移瘤的212例行PET CT检查,并回顾性分析其临床资料。结果212例中,肺原发恶性病变158例（745%）,其他部位原发恶性肿瘤40例（189%）,可疑脑原发病变11例（52%）,未发现原发灶的脑转移瘤3例（14%）。未明确原发灶的48例中,全身PET CT显像发现原发灶34例（708%）,其中肺恶性病变来源26例（542%）、其他部位来源恶性肿瘤8例（167%）。单纯胸部薄层CT扫描诊断为肺恶性病变来源者22例（458%）;CT性质不明确的孤立性肺结节4例,结合临床及全身PET CT显像特征均诊断为肺恶性病变。结论全身18F FDG PET CT显像有利于发现脑转移瘤的原发灶。脑转移瘤来源于肺恶性病变较多。胸部薄层CT扫描有利于对原发灶的初步诊断。     

18F-FDG PET/CT在寻找不明原发灶肿瘤患者原发灶中的价值

目的 探讨18F-FDG PET/CT在诊断不明原发灶肿瘤(CUP)患者原发灶中的价值.资料与方法 36例CUP患者行PET/CT检查拟寻找原发灶,根据转移灶部位分为淋巴结转移组(8例)、肝转移组(9例)、骨转移组(12例)及恶性胸腹水组(7例),比较18F-FDG PET/CT诊断淋巴结转移组与非淋巴结转移组CUP患者原发灶的灵敏度.结果 18F-FDG PET/CT寻找CUP原发灶的灵敏度为63.9％ (23/36),PET/CT诊断淋巴结转移组、肝转移组、骨转移组及恶性胸腹水组患者原发灶的灵敏度分别为87.5％ (7/8)、55.6％ (5/9)、58.3％(7/12)、57.1％ (4/7).18F-FDG PET/CT对淋巴结转移组原发灶的确诊率[87.5％(7/8)]显著高于非淋巴结转移组[57.1％( 16/28)],差异有统计学意义(P＜0.05).结论 18F-FDG PET/CT诊断CUP患者原发灶灵敏度较高,尤其适用于发生淋巴结转移的CUP患者.     

全身18F-FDGPET-CT在脑转移瘤诊断中的应用

目的评价全身18F-氟脱氧葡萄糖（18F-fluorodeoxyglucose,18 F-FDG）正电子发射断层扫描（posi—tronemissiontomography,PET）-CT显像在脑转移瘤的诊断及寻找原发灶中的应用价值。方法对全身脑转移瘤及可疑脑转移瘤的212例行PET—CT检查,并回顾性分析其临床资料。结果212例中,肺原发恶性病变158例（74．5％）,其他部位原发恶性肿瘤40例（18．9％）,可疑脑原发病变11例（5．2％）,未发现原发灶的脑转移瘤3例（1．4％）。未明确原发灶的48例中,全身PET-CT显像发现原发灶34例（70．8％）,其中肺恶性病变来源26例（54．2％）、其他部位来源恶性肿瘤8例（16．7％）。单纯胸部薄层CT扫描诊断为肺恶性病变来源者22例（45．8％）;CT性质不明确的孤立性肺结节4例,结合临床及全身PET—CT显像特征均诊断为肺恶性病变。结论全身18F—FDGPET—CT显像有利于发现脑转移瘤的原发灶。脑转移瘤来源于肺恶性病变较多。胸部薄层CT扫描有利于对原发灶的初步诊断。     

18F-FDG PET/CT与18F-FDG PET/MRI在卵巢癌临床应用中的进展

卵巢癌是妇科恶性肿瘤中病死率最高的肿瘤。18F-FDG PET/CT在卵巢癌的诊断、分期、疗效及预后的评估上优于常规影像技术,可以指导临床采取有针对性的治疗方案,以获得更好的治疗效果。PET/MRI是最近几年继PET/CT后投入临床应用的另外一种多模态影像技术,因其多序列成像、软组织分辨率较高和辐射剂量较低,对卵巢癌的诊治具有独特的优势。笔者对18F-FDG PET/CT和18F-FDG PET/MRI在卵巢癌中的临床应用进行综述。     

18F-FDG PET/CT显像在肾上腺转移瘤中的诊断价值和预测分析

目的探讨18F-FDG PET/CT显像在肾上腺转移瘤中的诊断价值及预测价值。方法回顾性分析2012年12月至2016年10月行PET/CT检查的95例无症状的肾上腺病变患者,分为肾上腺转移瘤组（40例）和肾上腺良性病变组（55例）,分别测量肾上腺病灶大小、CT值、最大标准化摄取值（SUV_max）、肾上腺病灶SUV_max/肝脏本底SUV_max比值（SUV_max比值）,分别进行单因素检验、独立样本t检验、Mann-Whitney U秩和检验统计分析。采用多因素Logistic回归分析肾上腺转移瘤的危险预测因素,并采用受试者工作特征（ROC）曲线分析确定肾上腺转移瘤与良性病变鉴别诊断的最佳临界点。结果110个肾上腺病灶中良性病变60个,转移瘤50个,大小为0.65~5.70 cm,平均（1.65±0.82）cm。CT值-20.4~46.8 HU,平均（24.2±14.9）HU。SUV_max为1.1~31.9,平均4.5±4.6。SUV_max比值为0.44~14.5,平均1.99±2.15。单因素分析得出两者在病灶大小、CT值、SUV_max、SUV_max比值之间的差异均有统计学意义（Z=-4.908、-6.030、-7.966、-8.252,均P < 0.001）;多因素Logistic回归分析显示SUV_max比值是影响肾上腺转移瘤发生的独立因素,ROC曲线分析得出SUV_max比值=1.24为鉴别诊断肾上腺转移瘤与良性病变的最佳临界点,灵敏度和特异度分别为90.0%和93.3%。结论18F-FDG PET/CT显像对肾上腺转移瘤具有较高的诊断价值。SUV_max比值是肾上腺转移瘤的独立危险预测因素,鉴别诊断肾上腺良性病变与转移瘤的SUV_max比值最佳临界点为1.24。     

18F-FDG PET/CT预测胃肠道间质瘤对伊马替尼治疗反应的Meta分析

目的通过Meta分析评价18F-FDG正电子发射计算机体层摄影(PET/CT)预测胃肠间质瘤对伊马替尼治疗反应的价值。方法检索PubMed、EMBASE、Web of science、Cochrane图书馆、中国知网、万方和中国生物医学数据库建库以来到2018年3月公开发表的PET/CT预测胃肠间质瘤对伊马替尼治疗反应的前瞻性试验,经2名研究人员进行数据提取和质量评价后,采用Meta-Disc软件进行双变量随机效应模型的Meta分析。通过绘制受试者操作特征(ROC)曲线并计算曲线下面积(AUC),计算纳入研究的合并敏感度、合并特异度、合并阳性似然比、合并阴性似然比、合并诊断比值比以及相应的95%置信区间(95%CI)。将接受治疗的药物类型和治疗后PET/CT的检查时间进行亚组分析,采用Meta回归探讨非阈值效应引起的异质性。结果共纳入6项研究,包括115例病人。纳入研究的合并敏感度、合并特异度、合并阳性似然比、合并阴性似然比、合并诊断比值比和AUC分别为0.88(95%CI:0.77～0.96)、0.64(95%CI:0.49～0.78)、2.03(95%CI:1.04～3.95)、0.27(95%CI:0.13～0.55)、11.43(95%CI:2.82～46.41)和0.8771。Meta回归分析显示所接受的治疗药物和治疗后PET/CT检查的时间对诊断价值的影响差异无统计学意义(P=0.29和0.68)。Deek’s漏斗图提示存在发表偏倚的可能性(P=0.04)。结论 18F-FDG PET/CT用于预测胃肠间质瘤对伊马替尼的治疗反应具有较高的敏感度和特异度。     

18F-FDG PET/CT在拟诊眼内转移瘤患者中的应用价值

目的 探讨眼内转移瘤18F-FDG PET/CT的影像学特点及临床应用价值。 方法 回顾性分析2011年3月至2019年2月于北京医院和首都医科大学附属北京同仁医院经病理学或临床确诊的眼内转移瘤患者53例（54只眼睛,其中1例为双眼转移）,其中男性23例、女性30例,年龄22~73（52.7±11.6）岁。所有患者行18F-FDG PET/CT检查,并对影像学表现特征及参数进行分析,包括最大标准化摄取值（SUV_max）和平均标准化摄取值（SUV_mean）;评估PET/CT对肿瘤原发灶的探查及其他部位转移灶发现的价值。多组计量资料之间的比较采用方差分析;相关性采用Pearson相关分析。 结果 眼内转移瘤CT形态多样,以梭形软组织影最为多见。47例可测量的眼内转移瘤CT值与SUV_max、SUV_mean均无明显线性关系（均r=?0.252,均P=0.088）。50例放射性摄取增高转移瘤的SUV_max、SUV_mean均与其长径、短径、上下径呈显著正相关（r=0.631~0.791,均P=0.000）。既往无肿瘤病史患者43例,PET/CT对原发灶的检出率为97.7%（42/43）,其中来源于肺癌36例、乳腺癌2例、食管癌、胃癌、鼻咽癌和前列腺癌各1例。PET/CT显示转移灶≥2个的患者51例（51/53,96.2%）,其中主要伴淋巴结转移43例（43/53,81.1%）、骨转移42例（42/53,79.2%）。 结论 眼内转移瘤CT形态多样,SUV仅与其大小有关。18F-FDG PET/CT在眼内转移瘤诊断、肿瘤原发灶的探查及其他部位转移灶的发现等方面具有重要的临床应用价值。     

胃肠道间质瘤18例的~(18)F-FDG PET/CT显像及病理对照研究

目的探讨胃肠道间质瘤的18F-FDG PET/CT显像特点及其相应病理学表现,以提高对胃肠道间质瘤的诊断水平。方法对18例病理证实为胃肠道间质瘤患者的PET/CT显像进行回顾性分析,记录、总结病灶特点,并与既往PET/CT报告及病理报告进行比较、分析。结果本组18例间质瘤,原发瘤灶均为单发,其中良性3例、潜在恶性5例、恶性10例,3例良性病变PET显像均为阴性表现,潜在恶性及恶性间质瘤15例均表现为均匀或不均匀核素异常浓聚灶,CT表现3例良性间质瘤均表现为边界清楚、光滑肿块影,潜在恶性及恶性间质瘤CT表现不一,多数病灶内可见坏死、囊变区,部分病灶内可见出血,少部分病灶内密度均匀,呈软组织密度;大部分病例可准确定位、定性诊断,少数病例定位诊断及病理学分型不明确。结论PET/CT在对间质瘤的定位及定性诊断方面具有重要价值,可鉴别间质瘤良、恶性,且一次扫描可判断肿瘤有无转移,但对于间质瘤恶性程度分级上还有一定困难,最后确诊有赖于病理组织学和免疫组化检查。     

18F-FDG PET/CT在不明原因发热病因学诊断中的应用

目的:探讨18F-FDG PET/CT在不明原因发热(FUO)病因诊断中的临床应用价值.方法:回顾性分析108例因FUO行18F-FDG PET/CT检查者的临床和影像资料.以病理学依据为诊断标准,不能获得病理诊断的以临床诊疗和随访结果作为诊断标准.统计PET/CT对FUO病因及不同病因组的诊断阳性率、灵敏度、特异度、...     

Giant Cell Tumor Pulmonary Metastases Mimic Primary Malignant Pulmonary Nodules on 18F-FDG PET/CT

A 59-year-old man with a 30-year history of multiple recurrences of a giant cell tumor (GCT) of the left knee was referred for an ¹⁸F-FDG PET/CT to evaluate a solitary pulmonary nodule. The nodule was mildly FDG-avid, raising suspicion of malignancy. It was excised and histologically proven to be a GCT pulmonary metastasis. A follow-up PET/CT done 2 years later revealed a new, larger lung mass that was more intensely FDG-avid, but of the same histology. This rare report highlights a pitfall in the evaluation of solitary pulmonary lesions by ¹⁸F-FDG PET/CT in patients with GCT of the bone.     

Prognostic Significance of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Operable Primary Breast Cancer

Purpose

We investigated whether PET indices measured by ¹⁸ F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) can predict prognosis in patients with operable primary breast cancer.

Methods

We reviewed 53 patients with operable primary breast cancer who underwent pretreatment FDG PET/CT. PET indices, maximum standardized uptake value (SUV) and metabolic tumor volume (MTV), were measured in the primary breast tumor (P), metastatic lymph nodes (N) and total tumor (T). The Cox proportional hazards model was used with age, tumor size, clinical lymph node status, method of surgery, presence or absence of neoadjuvant chemotherapy, histological type, histological grade, hormone receptors and HER2 status to predict disease-free survival (DFS) and overall survival (OS).

Results

Median follow-up period was 50 months (range, 17–73 months), during which 17 patients had recurrent disease and nine of whom died. The univariate analysis showed that high SUV of N (N_SUV, P = 0.011), MTV of N (N_MTV, P = 0.011) and MTV of T (T_MTV, P = 0.045) as well as high histological grade (P = 0.008), negative estrogen (P = 0.045) and negative progesterone (P = 0.029) receptor status were associated with shorter DFS. High N_SUV (P = 0.035), N_MTV (P = 0.035) and T_MTV (P = 0.035) as well as high histological grade (P = 0.012) and negative estrogen receptor status (P = 0.009) were associated with shorter OS. N_SUV, N_MTV and T_MTV were found to be significantly associated with high histological grade (P = 0.005). However, those failed to be statistically significant prognostic factors on multivariate analysis.

Conclusions

PET indices seem to be useful in the preoperative evaluation of prognosis in patients with operable primary breast cancer. N_SUV, N_MTV and T_MTV might be considerable factors associated with patient outcome in operable breast cancer.     

18F-FDOPA与18F-FDG PET/CT诊断脑肿瘤的系统评价

目的 系统评价18F-FDOPA与18F-FDG PET/CT显像在脑肿瘤诊断中的临床价值.方法 采用Meta分析与直接比较方法.使用计算机检索中国期刊全文数据库、中文科技期刊数据库、万方数据库、中国生物医学文献数据库、PubMed、Embase、The Cochrane Library,从建库至2016年10月,搜索直接比较18F-FDOPA与18F-FDG PET/CT诊断脑肿瘤的诊断性试验.用Meta-Disc 1.4软件进行分析,计算两种不同显像剂的合并敏感度(sensitivity,SEN)、合并特异度(specificity,SPE)、合并阳性似然比(positive likelihood ratio,+LR)、合并阴性似然比(negative likelihood ratio,-LR)、诊断优势比(diagnostic odds ratio,DOR),并绘制综合受试者工作特征曲线计算曲线下面积(area under curve,AUC)与Q*值.结果 最终共纳入4篇文章,Meta 分析结果显示,18F-FDOPA PET/CT对脑肿瘤诊断的合并SEN为0.97(95％ CI =0.90 ～ 1.00),SPE为0.67(95％ CI =0.45 ～0.84),+LR为2.31 (95％ CI=1.40 ～3.81),-LR为0.07 (95％ CI =0.02～ 0.24),DOR为39.72(95％ CI=8.94～176.48),AUC为0.9725,Q*为0.9239.18F-FDG PET/CT对脑肿瘤诊断的合并SEN为0.51(95％CI=0.39～0.63),SPE为0.75(95％ CI=0.53 ～0.90,+LR为l.59(95％ CI=0.70 ～ 3.61),-LR为0.63(95％ CI =0.47 ～0.86),DOR为2.55(95％ CI =0.82 ～7.92),AUC为0.5848,Q*为0.5638.结论 18F-FDOPA PET/CT显像诊断脑肿瘤的敏感性比18F-FDG高,对脑肿瘤具有良好的诊断价值,可作为脑肿瘤诊断的方法之一.     

Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology

OBJECTIVE: The purpose of these guidelines is to offer to the nuclear medicine team a framework that could prove helpful in daily practice. These guidelines contain information related to the indications, acquisition, processing and interpretation of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) in paediatric oncology. The Oncology Committee of the European Association of Nuclear Medicine (EANM) has published excellent procedure guidelines on tumour imaging with (18)F-FDG PET (Bombardieri et al., Eur J Nucl Med Mol Imaging 30:BP115-24, 2003). These guidelines, published by the EANM Paediatric Committee, do not intend to compete with the existing guidelines, but rather aim at providing additional information on issues particularly relevant to PET imaging of children with cancer. CONCLUSION: The guidelines summarize the views of the Paediatric Committee of the European Association of Nuclear Medicine. They should be taken in the context of "good practice" of nuclear medicine and of any national rules, which may apply to nuclear medicine examinations. The recommendations of these guidelines cannot be applied to all patients in all practice settings. The guidelines should not be deemed inclusive of all proper procedures or exclusive of other procedures reasonably directed to obtaining the same results.     

18F-FDG PET/CT对原发灶不明的骨转移瘤的诊断价值

目的探讨18F-FDGPET/CT对原发灶不明的骨转移瘤的诊断价值。资料与方法回顾性分析经病理证实的72例原发灶不明的骨转移瘤患者的PET/CT资料,记录原发灶部位、骨转移部位及骨外转移部位(包括前哨淋巴结及脏器)并按CT骨转移诊断标准进行分类,测量其最大标准摄取值。结果 PET/CT显像检查确定61例原发灶,11例未找到原发灶。66例为多发骨转移,6例为单发骨转移;原发灶部位依次为肺癌(31例)、前列腺癌(6例)、胃癌(4例)、结肠癌(3例)、甲状腺癌(3例)等;溶骨性转移以肺癌(22例)、胃肠癌(7例)多见,成骨性骨转移以前列腺癌(5例)、肺癌(4例)多见,混合性骨转移以肺癌(5例)、鼻咽癌(2例)多见;胸部骨及脊柱转移多见肺癌(31例),骨盆及脊柱转移多见肺癌(23例)、前列腺癌(6例)。结论 PET/CT诊断原发灶不明的骨转移瘤时,需根据骨转移的类型、部位及前哨淋巴结和脏器转移的位置找出原发灶,必要时进一步行穿刺活检明确诊断。     

Lung Adenocarcinoma Staged as an Unknown Primary Presenting with Symptomatic Colon Metastases: Staging by 18F-FDG PET/CT

A 66-year-old man, who presented with bright red blood per rectum, was referred for an ¹⁸F-FDG PET/CT after colonoscopy showed two suspicious colon masses, which were biopsied to reveal an adenocarcinoma of unknown origin. PET/CT showed two intensely FDG-avid colon masses as well as an unsuspected FDG-avid lung mass, which was biopsied to reveal a primary lung adenocarcinoma. Immunohistochemistry confirmed the two colon metastases were of pulmonary origin. It is extremely rare for lung carcinoma to present with symptomatic colon metastases, with only 11 cases described in the literature. We report the first case of the utility of ¹⁸F-FDG PET/CT in staging a patient who presented with symptomatic colon metastases of an unknown primary lung malignancy.     

6. 18F-FDG Whole Body Positron Emission Tomography (PET) in the Detection of Unknown Primary Tumors

Purpose: To evaluate the utility of FDG-PET in detecting primary tumors in patients with metastatic disease from unknown primary tumors.Methods: 12 patients with metastases from unknown origin after unsuccessful conventional diagnostic procedures were studied. 5 had lymph node metastases (2 axillary, 2 cervical, 1 mediastinal), 3 multiple metastases, 1 in the lung, 1 in the cava vein, 1 in the brain and 1 in adrenal glands. Patients received 400MBq FDG intravenously, and whole body images were acquired 60 min. after injection with an ECAT EXACT HR+. PET results were compared with histological and clinical findings.Results: All but one metastatic lesion was identified by PET. Additional metastases were visualized in 4 patients. In one helped to guide biopsy for histological diagnosis. In 4/11 patients FDG-PET did not reveal lesions suspected to be primary tumor. FDG-PET identified primary tumor in 8/11 patients (breast: 2, pancreas: 2, base of tongue: 1, adrenal gland: 1, lung: 1, stomach: 1). In 4 of them (33% of total) primary tumor was confirmed either histologically or by the clinical evolution (breast: 2, lung: 1, pancreas: 1). In 1 patient FDG-PET was false positive (base of tongue). 3 patients positive FDG-PET have not yet been confirmed. FDG-PET influenced therapeutic procedures in 4 patients (33% of total). 2 underwent surgery (breast), 1 received specific chemotherapy (lung) and 1 palliative chemotherapy (pancreas).Conclusions: Our preliminary results suggest that FDG-PET is a non-invasive technique useful in the detection of unknown primary tumors, can influence in selecting appropriate therapeutic management and could guide biopsies for histologic analysis.     

Value of 18F-FDG PET/CT in the Detection of Ovarian Malignancy

Purpose

Ovarian cancer is a leading cause of gynecologic malignancy. As symptoms of ovarian cancer are nonspecific, only 20 % of ovarian cancers are diagnosed while they are still limited to the ovaries. Thus, early and accurate detection of disease is important for an improved prognosis. For the accurate and effective diagnosis of ovarian malignancy on ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT), we analyzed several parameters, including visual assessment.

Method

A total of 51 peritoneal lesions in 19 patients who showed ovarian masses with diffuse peritoneal infiltration were enrolled. Twelve patients were confirmed to have ovarian malignancy and seven patients with benign disease by pathologic examination. All patients were examined by ¹⁸F-FDG PET/CT, and an additional 2-h delayed ¹⁸F-FDG PET/CT was also performed for 15 patients with 42 peritoneal lesions. We measured semiquantitative parameters including maximum and mean standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) on a 1-h initial ¹⁸F-FDG PET/CT image (Parameter₁) and on a 2-h delayed image (Parameter₂). Additionally, retention indices of each parameter were calculated, and each parameter among the malignant and benign lesions was compared by Mann-Whitney U test. We also assessed the visual characteristics of each peritoneal lesion, including metabolic extent, intensity, shape, heterogeneity, and total visual score. Associations between visual grades and malignancy were analyzed using linear by linear association methods. Moreover, a receiver operating characteristic (ROC) curve was analyzed to compare the effectiveness of significant parameters.

Result

In a comparison between the malignant and benign groups in the analysis of 51 total peritoneal lesions, SUVmax₁, SUVmean₁, and TLG₁ showed significant differences. Also, in the analysis of 42 peritoneal lesions that underwent an additional 2-h ¹⁸F-FDG PET/CT examination, SUVmax_1,2, SUVmean_1,2, TLG₂, and the RI of TLG showed significant differences between the malignant and benign groups. MTV did not show significant differences in either the analysis of 51 peritoneal lesions or of 42 lesions. Regarding visual assessments, metabolic intensity, shape, heterogeneity, and total visual score showed an association with malignancy. In the ROC analysis, the AUC of the visual score was larger than the AUC of other parameters in both the analyses of 51 peritoneal lesions and of 42 lesions.

Conclusion

Although further study with a larger patient population is needed, the visual assessment of ¹⁸F-FDG PET/CT imaging has a primary role in the detection of malignancy in ovarian cancer patients with assistance from other semi-quantitative parameters.     

Cavernous Hemangioma of the Ilium Mimicking Aggressive Malignant Bone Tumor with Increased Activity on 18F-FDG PET/CT

Osseous hemangioma is a benign vascular tumor, and it usually occurs in the vertebrae and the skull. However, hemangiomas of flat bones are rare, and there are very few reports that describe the radiologic findings of osseous hemangioma of the ilium. We report a unique case of large cavernous hemangioma mimicking a chondrogenic malignant bone tumor originated from the ilium in a 22-year-old female. The mass showed stippled calcifications, heterogeneous enhancement with thick septa and enhanced soft tissue components on CT and MR, and also this mass demonstrated heterogeneous 2-fluoro [fluorine-18]-2-deoxy-D-glucose (¹⁸F-FDG) uptake on ¹⁸F-FDG PET/CT.